The Potential of Tracer Kinetic Studies in Drug Development Programs: A New Investigational Area for Cancer Research

This paper covers a unique program created in the United Kingdom between the MRC Cyclotron Unit and the CRC Phase I and II drug development committee to investigate the potential of tracer kinetic studies to investigate in vivo tumor and normal tissue kinetics, molecular interactions, pathways, and mechanism of action of novel anti-cancer agents. Positron emission tomography technology offers great potential in streamlining anti-cancer drug development programs, however, significant investment in new methodology and multidisciplinary teams is necessary.